Patient information

How CartiONE Works

Current therapies for damaged cartilage in the knee are very invasive, expensive, and mostly offer a temporary solution for the patient. CartiONE is the only cost-effective therapy that will provide a fast hyaline- based single surgery. CartiONE is based on pivotal research conducted by one of the founders of this therapy.

2 Key Breakthroughs

Two key technology breakthroughs lead to the development of CartiONE:

  • a discovery of synergistic benefit in combining a limited number of isolated primary cartilage cells (chondrocytes) with the more abundant mononucleated cells from bone marrow, resulted in cartilage tissue generation. Preclinical testing demonstrated that this cell combination not only resulted in comparatively more cartilage tissue generation but the tissue was more similar in composition to the hyaline type cartilage found in articular joints such as the knee- allowing for flexibility and endurance
  • a rapid isolation method was developed that allowed the chondrocytes to be obtained from the cartilage tissue within approximately 45 minutes as opposed to the typical 24-hour protocols

These two discoveries are protected by a strong patent portfolio, enabling the development of CartiONE as the only cartilage repair technology that is fully autologous and can be delivered intraoperatively during a single surgical procedure.

One-Hour Cell Service

Freshly isolated chondrocytes enhanced with bone marrow cells in one surgery.

Cell-Based Cartilage Repair in One Surgery

Freshly isolated chondrocytes enhanced with bone marrow cells in one surgery.

Combination of fresh chondrocytes and bone-marrow cells
  • Cellular interaction improves production of physiological hyaline cartilage
  • Evidence shown in over 50 published papers
Patented Rapid Chondrocyte Isolation
  • 95% reduction in chondrocyte isolation time allows for single surgical procedure
  • Isolates the required amount of chondrocytes for cartilage regeneration process
  • Fresh non-cultured chondrocytes maintain their intrinsic potential for cartilage formation
Can be combined with a range of commercially available chondral and osteochondral membranes and carriers
  • Choice of carrier depends on defect type and surgeon’s preference
Preclinical Proof of Concept

R&D in-vivo study that demonstrates the superior chondrogenic potential of the cell combination over microfracture and ACI.

Comparing microfracture and ACI with CartiONE stained with  safranin-O

CartiONE (10% PCs + 90% MNCs
Microfracture (bone marrow cells)
Autologous Chondrocyte Implantation (ACI, cultured chondrocytes)

Immunostain for aggrecan and collagen type II, components typical for hyaline cartilage. Scaffold used: INSTRUCT.

Aggrecan
Collagen type II
Patient Interview
Patient Testimonial - CartiONE

CartiONE patient Tomaz describes his CartiONE surgery, rehabilitation and return to his pre-injury activities of Mountain Biking, Skiing and Rock Climbing. 

NOTE: The CartiONE cell service was originally launched as Instruct and is referred to in the study.